JP6489535B2 - 虚血再灌流障害の防御剤及び臓器の処置方法 - Google Patents
虚血再灌流障害の防御剤及び臓器の処置方法 Download PDFInfo
- Publication number
- JP6489535B2 JP6489535B2 JP2017078658A JP2017078658A JP6489535B2 JP 6489535 B2 JP6489535 B2 JP 6489535B2 JP 2017078658 A JP2017078658 A JP 2017078658A JP 2017078658 A JP2017078658 A JP 2017078658A JP 6489535 B2 JP6489535 B2 JP 6489535B2
- Authority
- JP
- Japan
- Prior art keywords
- organ
- group
- hydrogen
- perfusion
- ischemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000056 organ Anatomy 0.000 title claims description 69
- 238000000034 method Methods 0.000 title claims description 26
- 206010063837 Reperfusion injury Diseases 0.000 title claims description 20
- 208000028867 ischemia Diseases 0.000 title claims description 10
- 239000003223 protective agent Substances 0.000 title claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 71
- 239000001257 hydrogen Substances 0.000 claims description 65
- 229910052739 hydrogen Inorganic materials 0.000 claims description 65
- 230000010412 perfusion Effects 0.000 claims description 36
- 239000007788 liquid Substances 0.000 claims description 25
- 238000003860 storage Methods 0.000 claims description 17
- 238000002054 transplantation Methods 0.000 claims description 16
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 12
- 210000004204 blood vessel Anatomy 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 230000001629 suppression Effects 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 20
- 210000004185 liver Anatomy 0.000 description 16
- 239000000243 solution Substances 0.000 description 12
- 210000003240 portal vein Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 229960003180 glutathione Drugs 0.000 description 9
- 108010053070 Glutathione Disulfide Proteins 0.000 description 8
- 238000000540 analysis of variance Methods 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 239000003761 preservation solution Substances 0.000 description 8
- 210000000941 bile Anatomy 0.000 description 7
- 238000001361 intraarterial administration Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- 239000012891 Ringer solution Substances 0.000 description 6
- 210000002767 hepatic artery Anatomy 0.000 description 6
- 238000004321 preservation Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 5
- 101710190843 Carcinoembryonic antigen-related cell adhesion molecule 1 Proteins 0.000 description 5
- 108010024636 Glutathione Proteins 0.000 description 5
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 5
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 210000000013 bile duct Anatomy 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 239000000162 organ preservation solution Substances 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 230000010410 reperfusion Effects 0.000 description 5
- 206010019837 Hepatocellular injury Diseases 0.000 description 4
- 102100037907 High mobility group protein B1 Human genes 0.000 description 4
- 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 description 4
- 210000001736 capillary Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000000082 organ preservation Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 208000013200 Stress disease Diseases 0.000 description 3
- 239000000524 Thiobarbituric Acid Reactive Substance Substances 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- 102000003929 Transaminases Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 231100000437 hepatocellular injury Toxicity 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 230000008816 organ damage Effects 0.000 description 3
- 238000010149 post-hoc-test Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 208000007204 Brain death Diseases 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000010246 ultrastructural analysis Methods 0.000 description 2
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 1
- 208000015163 Biliary Tract disease Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 108700042768 University of Wisconsin-lactobionate solution Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
Description
<臓器の調製>
Wistar系雄性ラット(体重270〜320g)から肝臓を全摘出し、UW(University of Wisconsin)液に24時間冷保存(4℃)した。
<水素含有保存液の調整>
非破壊水素含有法(MiZ株式会社、特許第5935954号)を用いて、保存液に水素を溶解させ、水素含有保存液を調製した。具体的には、Ringer液が入った滅菌済みの点滴バッグ(扶桑薬品工業社製、500ml)を、湿らせた水素発生剤(MiZ株式会社製)と共にアルミバッグの中に入れ真空処理した。このアルミバッグを約24時間、室温で放置し、水素を発生させ、点滴バッグ中に無菌的に水素を溶存させた。溶存水素濃度判定試薬(MiZ株式会社製)及び電気化学式水素濃度計(東亜DKK社製DHD1−1型)で水素濃度を測定したところ、保存液中の水素濃度は1mg/L(1ppm)であった。
上記24時間冷保存した肝臓10検体を1群として、下記[1]〜[4]群の灌流処置を施してから、移植用臓器の評価系である酸素化体外灌流(37℃、2時間)を行った後、肝障害や肝機能を測定した。
[1]25℃に保温した、水素を含有しない通常のRinger液40mLを門脈から灌流する群(以下、Control群)、
[2]25℃に保温した、水素を含有するRinger液(1.0ppm)を用いて、門脈から40mLを灌流する群(以下、H2−PV群)、
[3]25℃に保温した、水素を含有するRinger液(1.0ppm)を用いて、肝動脈から40mLを灌流する群(以下、H2−HA群)、
[4]25℃に保温した、水素を含有するRinger液(1.0ppm)を用いて、門脈と肝動脈の両方からそれぞれ40mLと20mLを灌流する群(以下、H2−PV+HA群)。
肝細胞障害マーカーであるトランスアミナーゼ遊離に対する影響を、図1に示した。図示するアスパラギン酸アミノトランスフェラーゼ(AST)、アラニンアミノトランスフェラーゼ(ALT)および乳酸脱水素酵素(LDH)の各結果について分散分析を行うと、それぞれp=0.0005、p=0.0011およびp=0.0013でいずれも統計学的に有意差を示し、さらに多重比較検定を行うと、いずれのマーカーにおいてもControl群と、H2−PV群、H2−HA群またはH2−PV+HA群の間に統計学的な有意差(p<0.05、p<0.01、またはp<0.0001)が見られた。この結果は、水素含有保存液で処置した群ではトランスアミナーゼ遊離が抑制され、肝細胞障害が極めて軽微であることを示している。
Claims (5)
- 1.6ppm以下の濃度の水素分子を含有する液体からなり、かつ該液体が、移植用臓器の冷保存終了後、冷温で該臓器の血管から体外で灌流され、それによって該臓器の虚血再灌流障害を防御するために使用されるものであることを特徴とする、移植用臓器の虚血再灌流障害の防御剤。
- 前記水素分子を含有する液体が、無菌的に水素分子を溶存して得られるものであることを特徴とする、請求項1に記載の防御剤。
- 1.6ppm以下の濃度の水素分子を含有する液体を、移植用臓器の冷保存終了後、冷温で該臓器の血管から体外で灌流することを含むことを特徴とする、移植用臓器の虚血再灌流障害抑制方法。
- 移植用臓器を、冷保存終了後、冷温で該臓器の血管から1.6ppm以下の濃度の水素分子を含有する液体を体外で灌流することを含むことを特徴とする、移植用臓器の処置方法。
- 前記水素分子を含有する液体が、無菌的に水素分子を溶存して得られるものであることを特徴とする、請求項3または4に記載の方法。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017078658A JP6489535B2 (ja) | 2017-04-12 | 2017-04-12 | 虚血再灌流障害の防御剤及び臓器の処置方法 |
US15/950,383 US20180295833A1 (en) | 2017-04-12 | 2018-04-11 | Method for suppression of or protection from ischemia/reperfusion injury of organs for transplantation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017078658A JP6489535B2 (ja) | 2017-04-12 | 2017-04-12 | 虚血再灌流障害の防御剤及び臓器の処置方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018177683A JP2018177683A (ja) | 2018-11-15 |
JP6489535B2 true JP6489535B2 (ja) | 2019-03-27 |
Family
ID=63791234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017078658A Active JP6489535B2 (ja) | 2017-04-12 | 2017-04-12 | 虚血再灌流障害の防御剤及び臓器の処置方法 |
Country Status (2)
Country | Link |
---|---|
US (1) | US20180295833A1 (ja) |
JP (1) | JP6489535B2 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020217575A1 (ja) * | 2019-04-23 | 2020-10-29 | 学校法人慶應義塾 | 水素含有臓器保存液の生成方法及び水素含有臓器保存液 |
GR1009935B (el) * | 2019-11-15 | 2021-02-19 | Κυριακος Κωνσταντινου Κοτζαμπασης | Μεθοδος λειτουργικης συντηρησης (μικρο)οργανισμων και προϊοντων σε ατμοσφαιρα υδρογονου |
WO2024048479A1 (ja) * | 2022-08-30 | 2024-03-07 | 国立大学法人東北大学 | 虚血再灌流傷害抑制 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2522941A1 (en) * | 2003-04-23 | 2004-11-04 | Human Biosystems | Improved methods and solutions for storing donor organs |
JP2005306749A (ja) * | 2004-04-19 | 2005-11-04 | Kringle Pharma Inc | Hgf含有臓器保存液 |
JP4967001B2 (ja) * | 2009-03-13 | 2012-07-04 | ミズ株式会社 | 水素含有生体適用液の製造方法、及びそのための装置 |
-
2017
- 2017-04-12 JP JP2017078658A patent/JP6489535B2/ja active Active
-
2018
- 2018-04-11 US US15/950,383 patent/US20180295833A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20180295833A1 (en) | 2018-10-18 |
JP2018177683A (ja) | 2018-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2263674T5 (es) | Disolución de evaluación y conservación . | |
Okamura et al. | Impact of subnormothermic machine perfusion preservation in severely steatotic rat livers: a detailed assessment in an isolated setting | |
JP6489535B2 (ja) | 虚血再灌流障害の防御剤及び臓器の処置方法 | |
US20020115634A1 (en) | Organ and biological tissue preservation cold storage solution | |
Reiling et al. | Assessment and transplantation of orphan donor livers: a back‐to‐base approach to normothermic machine perfusion | |
Pizarro et al. | Protective effects of a carbon monoxide-releasing molecule (CORM-3) during hepatic cold preservation | |
JPH07196401A (ja) | 移植器官の保存のための方法、装置及び潅流液 | |
JP2008519830A (ja) | 臓器の冷却保存および灌流のための組成物 | |
Bhardwaj et al. | The effect of arginine and nitric oxide on resistance blood vessels of the perfused rat kidney | |
Tatum et al. | Machine perfusion of donor organs for transplantation | |
Hijiya et al. | Bronchodilator inhalation during ex vivo lung perfusion improves posttransplant graft function after warm ischemia | |
WO2010049996A1 (ja) | 哺乳動物の臓器の保存方法 | |
Song et al. | Cryopreservation of the common carotid artery of the rabbit | |
Balaban et al. | Delivery of the bioactive gas hydrogen sulfide during cold preservation of rat liver: effects on hepatic function in an ex vivo model | |
Tamaki et al. | Hydrogen flush after cold storage as a new end‐ischemic ex vivo treatment for liver grafts against ischemia/reperfusion injury | |
Okumura et al. | Liver graft preservation using perfluorocarbon improves the outcomes of simulated donation after cardiac death liver transplantation in rats | |
Aeba et al. | University of Wisconsin solution for pulmonary preservation in a rat transplant model | |
EP3150067A1 (en) | Organ preservation solution | |
López-Martínez et al. | Normothermic machine perfusion systems: where do we go from here? | |
WO2007043698A1 (ja) | 肝臓保存液 | |
Dahm et al. | Activated neutrophils injure the isolated, perfused rat liver by an oxygen radical-dependent mechanism. | |
Carnevale et al. | The Novel N, N‐bis‐2‐Hydroxyethyl‐2‐Aminoethanesulfonic Acid–Gluconate–Polyethylene Glycol–Hypothermic Machine Perfusion Solution Improves Static Cold Storage and Reduces Ischemia/Reperfusion Injury in Rat Liver Transplant | |
Jain et al. | University of Wisconsin versus histidine-tryptophan-ketoglutarate for tissue preservation in live-donor liver transplantation | |
Třeška et al. | Can ischemia-reperfusion syndrome in transplanted kidneys procured from non–heart-beating donors be influenced by adding selenium into the reperfusion solution? an experimental study | |
Ishitsuka et al. | Comparative effects of phosphoenolpyruvate, a glycolytic intermediate, as an organ preservation agent with glucose and N-acetylcysteine against organ damage during cold storage of mouse liver and kidney |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180814 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181012 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181213 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190129 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190218 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6489535 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |